180 related articles for article (PubMed ID: 10800060)
1. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.
Valteau-Couanet D; Benhamou E; Vassal G; Stambouli F; Lapierre V; Couanet D; Lumbroso J; Hartmann O
Bone Marrow Transplant; 2000 May; 25(9):937-42. PubMed ID: 10800060
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.
Hartmann O; Valteau-Couanet D; Vassal G; Lapierre V; Brugières L; Delgado R; Couanet D; Lumbroso J; Benhamou E
Bone Marrow Transplant; 1999 Apr; 23(8):789-95. PubMed ID: 10231141
[TBL] [Abstract][Full Text] [Related]
3. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
[TBL] [Abstract][Full Text] [Related]
4. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
7. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
[TBL] [Abstract][Full Text] [Related]
8. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic neuroblastoma: consolidation treatment with 2 courses of high-dose chemotherapy followed by a bone marrow autograft].
Hartmann O; Benhamou E; Beaujean F; Kalifa C; Lejars O; Patte C; Behard C; Flamant F; Thyss A; Deville A
Bull Cancer; 1988; 75(1):119-23. PubMed ID: 3282574
[TBL] [Abstract][Full Text] [Related]
10. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.
Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M
Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055
[TBL] [Abstract][Full Text] [Related]
11. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
Gutierrez-Delgado F; Holmberg LA; Hooper H; Appelbaum FR; Livingston RB; Maziarz RT; Weiden P; Rivkin S; Montgomery P; Kawahara K; Bensinger W
Bone Marrow Transplant; 2000 Jul; 26(1):51-9. PubMed ID: 10918405
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
13. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
[TBL] [Abstract][Full Text] [Related]
14. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
15. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
[TBL] [Abstract][Full Text] [Related]
16. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
17. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
18. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
19. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Yonemoto T; Tatezaki S; Ishii T; Satoh T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1431-5. PubMed ID: 10500530
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
